The article you requested is
Paul E. Keck, Jr., Jerry A. Bennett, and Sean P. Stanton Reply
J Clin Psychiatry 1997;58:496 [letter]
Copyright 1997 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: We thank Drs. Dardennes and Even for their interest in
our article and for their comments. Our conclusions from the decision-
analytic model proposed in our article were that, based
on the available evidence, divalproex appeared to be less costly
overall in the treatment of patients with bipolar disorder, but
that cost differences were also dependent on the type of manic
syndrome. For patients with classic mania, lithium appeared to
be less costly, whereas for mixed mania or rapid cycling, divalproex
appeared to have a cost advantage.